Lauren classification and individualized chemotherapy in gastric cancer

Karimi, 2014, Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention, Cancer Epidemiol Biomarkers Prev, 23, 700, 10.1158/1055-9965.EPI-13-1057

Guggenheim, 2013, Gastric cancer epidemiology and risk factors, J Surg Oncol, 107, 230, 10.1002/jso.23262

Crew, 2006, Epidemiology of gastric cancer, World J Gastroenterol, 12, 354, 10.3748/wjg.v12.i3.354

Patru, 2013, Current issues in gastric cancer epidemiology, Rev Med Chir Soc Med Nat Iasi, 117, 199

Lauren, 1965, The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification, Acta Pathol Microbiol Scand, 64, 31, 10.1111/apm.1965.64.1.31

Qiu, 2013, Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China, J Transl Med, 11, 58, 10.1186/1479-5876-11-58

Zheng, 2007, Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: An immunostaining study on the tissue microarray, J Clin Pathol, 60, 273, 10.1136/jcp.2006.038778

Chen, 2016, Clinicopathological variation of lauren classification in gastric cancer, Pathol Oncol Res, 22, 197, 10.1007/s12253-015-9996-6

Hommel, 2012, Diffuse gastric cancer with peritoneal carcinomatosis can mimic Crohn's disease, Case Rep Gastroenterol, 6, 695, 10.1159/000345385

Stiekema, 2013, Surgical treatment results of intestinal and diffuse type gastric cancer, Implications for a differentiated therapeutic approach? Eur J Surg Oncol, 39, 686, 10.1016/j.ejso.2013.02.026

Kaneko, 2001, Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989, Br J Cancer, 84, 400, 10.1054/bjoc.2000.1602

Yamamoto, 2011, Role of DNA methylation in the development of diffuse-type gastric cancer, Digestion, 83, 241, 10.1159/000320453

Fu, 2015, Epigenetic alterations in gastric cancer, Mol Med Rep, 12, 3223, 10.3892/mmr.2015.3816

Martínez-Madrigal, 2000, Atypical regenerative changes, dysplasia, and carcinoma in situ in chronic gastritis associated with Helicobacter pylori, Rev Gastroenterol Mex, 65, 11

Kodama, 2012, Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation, Digestion, 85, 126, 10.1159/000334684

Asaka, 2012, Elimination of gastric cancer from Japan, Nihon Rinsho, 70, 1667

Take, 2011, The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori, J Gastroenterol, 46, 318, 10.1007/s00535-010-0347-9

Vannella, 2012, Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal, World J Gastroenterol, 18, 1279, 10.3748/wjg.v18.i12.1279

Rokkas, 2007, The long-term impact of Helicobacter pylori eradication on gastric histology: A systematic review and meta-analysis, Helicobacter, 12, S32, 10.1111/j.1523-5378.2007.00563.x

Maehata, 2012, Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer, Gastrointest Endosc, 75, 39, 10.1016/j.gie.2011.08.030

Pereyra, 2011, Diffuse gastric cancer associated with Ménétrier's disease, Acta Gastroenterol Latinoam, 41, 142

Palestro, 2005, Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy, World J Gastroenterol, 11, 7131, 10.3748/wjg.v11.i45.7131

Nardone, 2004, Review article: Helicobacter pylori and molecular events in precancerous gastric lesions, Aliment Pharmacol Ther, 20, 261, 10.1111/j.1365-2036.2004.02075.x

Yoshida, 2013, Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis, Gastric Cancer, 16, 488, 10.1007/s10120-012-0230-x

Corso, 2011, Familial gastric cancer: Update for practice management, Fam Cancer, 10, 391, 10.1007/s10689-010-9410-1

Oliveira, 2015, Familial gastric cancer: Genetic susceptibility, pathology, and implications for management, Lancet Oncol, 16, e60, 10.1016/S1470-2045(14)71016-2

Vogelaar, 2012, Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology, Hered Cancer Clin Pract, 10, 18, 10.1186/1897-4287-10-18

Carneiro, 2012, Hereditary gastric cancer, Pathologe, 33, S231, 10.1007/s00292-012-1677-6

Machado, 2001, E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma, Oncogene, 20, 1525, 10.1038/sj.onc.1204234

Kim, 2004, A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome, J Hum Genet, 49, 591, 10.1007/s10038-004-0193-9

Kim, 2013, Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients, Fam Cancer, 12, 503, 10.1007/s10689-012-9595-6

Bacani, 2006, CDH1/E-cadherin germline mutations in early-onset gastric cancer, J Med Genet, 43, 867, 10.1136/jmg.2006.043133

Corso, 2011, E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer, Eur J Cancer, 47, 631, 10.1016/j.ejca.2010.10.011

Humar, 2002, Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer, Oncogene, 21, 8192, 10.1038/sj.onc.1205921

Liu, 2006, Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas, World J Gastroenterol, 12, 2168, 10.3748/wjg.v12.i14.2168

Ramos-de la Medina, 2006, Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer, Rev Esp Enferm Dig, 98, 36, 10.4321/S1130-01082006000100005

Hoogerbrugge, 2006, Preventive resection of hereditary diffuse gastric cancer, Ned Tijdschr Geneeskd, 150, 2417

Kluijt, 2011, Familial gastric cancer: Diagnosis, treatment and periodic surveillance, Ned Tijdschr Geneeskd, 155, A2731

Schildberg, 2014, Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations, Adv Med Sci, 59, 142, 10.1016/j.advms.2014.03.002

Kim, 2011, High microsatellite instability predicts good prognosis in intestinal-type gastric cancers, J Gastroenterol Hepatol, 26, 585, 10.1111/j.1440-1746.2010.06487.x

Qiu, 2014, Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients, BMC Cancer, 14, 823, 10.1186/1471-2407-14-823

Wu, 2005, Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis, World J Gastroenterol, 11, 3139, 10.3748/wjg.v11.i20.3139

Lazăr, 2008, The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival, Rom J Morphol Embryol, 49, 459

Stănculescu, 2011, E-cadherin in gastric carcinomas related to histological prognostic parameters, Rom J Morphol Embryol, 52, S1107

Karayiannakis, 1998, E-cadherin expression as a differentiation marker in gastric cancer, Hepatogastroenterology, 45, 2437

Asano, 2016, Cdx2 expression and intestinal metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses, Cancer Res, 10.1158/0008-5472.CAN-15-2272

Almeida, 2005, OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells, J Pathol, 207, 396, 10.1002/path.1861

Mesquita, 2003, Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines, J Biol Chem, 278, 51549, 10.1074/jbc.M309019200

Kim, 2006, CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions, J Gastroenterol Hepatol, 21, 438, 10.1111/j.1440-1746.2005.03933.x

Seno, 2002, CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications, Int J Oncol, 21, 769

Mizoshita, 2003, Expression of Cdx2 and the phenotype of advanced gastric cancers: Relationship with prognosis, J Cancer Res Clin Oncol, 129, 727, 10.1007/s00432-003-0499-6

Fan, 2005, Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: Correlation with histologic type and implications for prognosis, Clin Cancer Res, 11, 6162, 10.1158/1078-0432.CCR-05-0278

Fang, 2012, Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery, World J Surg, 36, 2131, 10.1007/s00268-012-1652-7

Kim, 2013, Microsatellite instability status in gastric cancer: A reappraisal of its clinical significance and relationship with mucin phenotypes, Korean J Pathol, 47, 28, 10.4132/KoreanJPathol.2013.47.1.28

Yuan, 2016, Targeted therapy for gastric cancer: Current status and future directions, Oncol Rep, 35, 1245, 10.3892/or.2015.4528

Park, 2006, HER-2/neu amplification is an independent prognostic factor in gastric cancer, Dig Dis Sci, 51, 1371, 10.1007/s10620-005-9057-1

Janjigian, 2012, Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis, Ann Oncol, 23, 2656, 10.1093/annonc/mds104

Sornmayura, 2012, Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients, J Med Assoc Thai, 95, 88

Ishida, 2016, Trastuzumab-based photoimmunotherapy integrated with viral HER2 transduction inhibits peritoneally disseminated HER2-negative cancer, Mol Cancer Ther, 10.1158/1535-7163.MCT-15-0644

Gagliato, 2016, Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer, Oncotarget, 10.18632/oncotarget.7043

Liu, 2012, HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients, J Clin Gastroenterol, 46, e31, 10.1097/MCG.0b013e31823457ea

Wu, 2011, Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma, Zhonghua Bing Li Xue Za Zhi, 40, 296

Förster, 2011, THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling, Mod Pathol, 24, 1390, 10.1038/modpathol.2011.99

Kim, 2005, Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach, Cancer, 103, 1439, 10.1002/cncr.20966

Zhao, 2015, Trop2 is overexpressed in gastric cancer and predicts poor prognosis, Oncotarget

He, 2012, Association of transcriptional repressor Snail with Lauren classification of gastric cancer, Zhonghua Wei Chang Wai Ke Za Zhi, 15, 852

Jackson, 2007, Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy, Oncology (Williston Park), 21, 1084

Park, 2011, CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients, Br J Cancer, 104, 1126, 10.1038/bjc.2011.24

Wang, 2012, Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: A systematic review, BMC Gastroenterol, 12, 137, 10.1186/1471-230X-12-137

Takahari, 2014, Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912, Oncologist, 19, 358, 10.1634/theoncologist.2013-0306

Ajani, 2010, Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial, J Clin Oncol, 28, 1547, 10.1200/JCO.2009.25.4706

Narahara, 2011, Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002), Gastric Cancer, 14, 72, 10.1007/s10120-011-0009-5

Boku, 2009, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study, Lancet Oncol, 10, 1063, 10.1016/S1470-2045(09)70259-1

Yamaguchi, 2002, Paclitaxel Gastric Cancer Study Group in Japan: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer, Gastric Cancer, 5, 90, 10.1007/s101200200015

Kato, 2012, Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer, Invest New Drugs, 30, 1621, 10.1007/s10637-011-9709-2

Koizumi, 2014, JACCRO and KCSG Study Group: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START), J Cancer Res Clin Oncol, 140, 319, 10.1007/s00432-013-1563-5

Kobayashi, 2006, Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients, World J Gastroenterol, 12, 1412, 10.3748/wjg.v12.i9.1412

Kitayama, 2012, S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis, Gastrointest Cancer Res, 5, S10

Toriumi, 2004, Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma, Anticancer Res, 24, 2455